| Attribute |
Value |
| 52 Week Change |
0.15826571 |
| Address1 |
333 Lakeside Drive |
| All Time High |
157.29 |
| All Time Low |
0.207031 |
| Ask |
137.59 |
| Ask Size |
1 |
| Audit Risk |
9 |
| Average Analyst Rating |
1.6 - Buy |
| Average Daily Volume10 Day |
8,909,330 |
| Average Daily Volume3 Month |
7,500,134 |
| Average Volume |
7,500,134 |
| Average Volume10Days |
8,909,330 |
| Beta |
0.343 |
| Bid |
122.5 |
| Bid Size |
1 |
| Board Risk |
5 |
| Book Value |
18.933 |
| City |
Foster City |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
8 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
131.4 |
| Current Ratio |
1.967 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
131.67 |
| Day Low |
127.935 |
| Debt To Equity |
94.635 |
| Display Name |
Gilead Sciences |
| Dividend Date |
1,782,691,200 |
| Dividend Rate |
3.28 |
| Dividend Yield |
2.53 |
| Earnings Call Timestamp End |
1,778,185,800 |
| Earnings Call Timestamp Start |
1,778,185,800 |
| Earnings Growth |
0.548 |
| Earnings Quarterly Growth |
0.537 |
| Earnings Timestamp |
1,778,184,000 |
| Earnings Timestamp End |
1,786,046,400 |
| Earnings Timestamp Start |
1,786,046,400 |
| Ebitda |
14,737,999,872 |
| Ebitda Margins |
0.49563 |
| Enterprise To Ebitda |
11.902 |
| Enterprise To Revenue |
5.899 |
| Enterprise Value |
175,415,279,616 |
| Eps Current Year |
-0.77187 |
| Eps Forward |
9.71019 |
| Eps Trailing Twelve Months |
7.35 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,781,481,600 |
| Exchange |
NMS |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fax |
650 522 5853 |
| Fifty Day Average |
129.8516 |
| Fifty Day Average Change |
1.5484009 |
| Fifty Day Average Change Percent |
0.011924389 |
| Fifty Two Week Change Percent |
15.8265705 |
| Fifty Two Week High |
157.29 |
| Fifty Two Week High Change |
-25.89 |
| Fifty Two Week High Change Percent |
-0.16460042 |
| Fifty Two Week Low |
107.75 |
| Fifty Two Week Low Change |
23.649994 |
| Fifty Two Week Low Change Percent |
0.2194895 |
| Fifty Two Week Range |
107.75 - 157.29 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
696,090,600,000 |
| Five Year Avg Dividend Yield |
3.62 |
| Float Shares |
1,238,826,005 |
| Forward Eps |
9.71019 |
| Forward P E |
13.532176 |
| Free Cashflow |
7,934,125,056 |
| Full Exchange Name |
NasdaqGS |
| Full Time Employees |
17,000 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,782,864,000 |
| Gross Margins |
0.79367995 |
| Gross Profits |
23,601,000,448 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.00118 |
| Held Percent Institutions |
0.92217004 |
| Implied Shares Outstanding |
1,241,569,874 |
| Industry |
Drug Manufacturers - General |
| Industry Disp |
Drug Manufacturers - General |
| Industry Key |
drug-manufacturers-general |
| Ir Website |
http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-irhome |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Dividend Date |
1,781,481,600 |
| Last Dividend Value |
0.82 |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,359,331,200 |
| Last Split Factor |
2:1 |
| Long Business Summary |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California. |
| Long Name |
Gilead Sciences, Inc. |
| Market |
us_market |
| Market Cap |
163,142,287,360 |
| Market State |
POSTPOST |
| Max Age |
86,400 |
| Message Board Id |
finmb_29002 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
9,216,000,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
161,193,016,741 |
| Number Of Analyst Opinions |
27 |
| Open |
129.68 |
| Operating Cashflow |
10,805,999,616 |
| Operating Margins |
0.39282 |
| Overall Risk |
5 |
| Payout Ratio |
0.43400002 |
| Peg Ratio |
2.14 |
| Phone |
650 574 3000 |
| Post Market Change |
0.05000305 |
| Post Market Change Percent |
0.038054075 |
| Post Market Price |
131.45 |
| Post Market Time |
1,783,987,177 |
| Previous Close |
129.83 |
| Price Eps Current Year |
-170.23592 |
| Price Hint |
2 |
| Price To Book |
6.9402623 |
| Price To Sales Trailing12 Months |
5.4863563 |
| Profit Margins |
0.30993 |
| Quick Ratio |
1.536 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
buy |
| Recommendation Mean |
1.62069 |
| Region |
US |
| Regular Market Change |
1.56999 |
| Regular Market Change Percent |
1.20927 |
| Regular Market Day High |
131.67 |
| Regular Market Day Low |
127.935 |
| Regular Market Day Range |
127.935 - 131.67 |
| Regular Market Open |
129.68 |
| Regular Market Previous Close |
129.83 |
| Regular Market Price |
131.4 |
| Regular Market Time |
1,783,972,801 |
| Regular Market Volume |
5,075,691 |
| Return On Assets |
0.13292 |
| Return On Equity |
0.4336 |
| Revenue Growth |
0.044 |
| Revenue Per Share |
23.923 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
2 |
| Shares Outstanding |
1,241,569,874 |
| Shares Percent Shares Out |
0.020499999 |
| Shares Short |
25,484,358 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
25,725,417 |
| Short Name |
Gilead Sciences, Inc. |
| Short Percent Of Float |
0.020499999 |
| Short Ratio |
2.73 |
| Source Interval |
15 |
| State |
CA |
| Symbol |
GILD |
| Target High Price |
180.0 |
| Target Low Price |
120.0 |
| Target Mean Price |
158.2963 |
| Target Median Price |
160.0 |
| Total Cash |
9,816,999,936 |
| Total Cash Per Share |
7.907 |
| Total Debt |
22,173,999,104 |
| Total Revenue |
29,735,999,488 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
3.19 |
| Trailing Annual Dividend Yield |
0.024570592 |
| Trailing Eps |
7.35 |
| Trailing P E |
17.87755 |
| Trailing Peg Ratio |
2.1441 |
| Triggerable |
1 |
| Two Hundred Day Average |
130.43684 |
| Two Hundred Day Average Change |
0.96315 |
| Two Hundred Day Average Change Percent |
0.0073840334 |
| Type Disp |
Equity |
| Volume |
5,075,691 |
| Website |
https://www.gilead.com |
| Zip |
94,404 |